Physician profile
Thomas Aaron Buice
NPI 1194754648
$1,330.97
in general payments reported to CMS, 2019-2025
24 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $129 · 2021: $142 · 2022: $451 · 2023: $42.00 · 2024: $164 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $514.28 | 2019-2024 | Puraply, Apligraf |
| Abbvie INC. | $75.32 | 2021-2022 | |
| Exact Sciences Corporation | $71.43 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $65.08 | 2024 | Wegovy, Rybelsus, Ozempic |
| Paratek Pharmaceuticals, INC. | $60.61 | 2025 | Nuzyra |
| Amgen INC. | $59.94 | 2022-2024 | Repatha, Otezla |
| Smith+Nephew, INC. | $55.27 | 2019-2022 | |
| Corcept Therapeutics | $51.14 | 2022-2025 | Korlym |
| Lilly USA, LLC | $50.99 | 2025 | Mounjaro, Zepbound |
| Aroa Biosurgery Incorporated | $47.78 | 2020 | |
| Glaxosmithkline, LLC. | $37.04 | 2024-2025 | Trelegy Ellipta |
| Dexcom, INC. | $32.52 | 2022 | |
| Melinta Therapeutics, LLC | $26.24 | 2021 | |
| Cardiovascular Systems INC. | $23.03 | 2020 | |
| Kci USA, INC. | $19.26 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.14 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.47 | 2025 | Fanapt |
| Reapplix INC. | $17.09 | 2023 | 3c Patch Kit - Box |
| Teva Pharmaceuticals USA, INC. | $16.99 | 2021 | |
| Abbott Laboratories | $16.00 | 2021 | |
| Bioventus LLC | $15.73 | 2022 | |
| Hydrofera LLC | $14.52 | 2022 | |
| Molnlycke Health Care US, LLC | $13.01 | 2024 | Avance |
| Sanofi Pasteur INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Buice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.